Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
207419 participants
OBSERVATIONAL
2012-01-01
2023-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Can frailty successfully predict outcomes in cardiogenic shock?
* Whether the impact of frailty would differ with age in cardiogenic shock?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
NCT06427304
Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions
NCT01845207
Relationship Between Coronary Microvascular Dysfunction and Improvement of Left Ventricular Systolic Function in Patients With Heart Failure With Reduced Ejection Fraction Caused by Non-ischemic Etiology
NCT06243653
Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
NCT02798705
The Current Status and Clinical Outcomes of Patients With Cardiogenic Shock II
NCT04143893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with a documented history of shock in the year before the index admission
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ki Hong Choi
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS Frailty
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.